PDE10A-IN-2 hydrochloride,98.43%

产品编号:Bellancom-131973| 分子式:C33H38Cl3N5O| 分子量:627.05

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-131973
3500.00 杭州 北京(现货)
Bellancom-131973
6000.00 杭州 北京(现货)
Bellancom-131973
12500.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

PDE10A-IN-2 hydrochloride

产品介绍 PDE10A-IN-2 hydrochloride 是一种有效的,高选择性,具有口服活性的 磷酸二酯酶 10A (PDE10A) 的抑制剂,IC50 为 2.8 nM。PDE10A-IN-2 hydrochloride 对其他 PDE 亚型显示出大于 3500 倍的选择性,并可用于肺动脉高压 (PAH) 的研究。
生物活性

PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active phosphodiesterase 10A (PDE10A) inhibitor with an IC50 of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes. PDE10A-IN-2 hydrochloride can be used for pulmonary arterial hypertension (PAH) research.

体外研究
体内研究

PDE10A-IN-2 hydrochloride (compound 14 3HCL; 2.5 mg/kg; oral administration; daily; for 3 weeks) treatment decreases the typical symptoms of PAH in rats.
In Sprague-Dawley rats, the pharmacokinetic study of PDE10A-IN-2 hydrochloride (compound 14 3HCL; 10 mg/kg) shows the oral bioavailability up to ∼50%, and the T1/2 is 5.2 hours (p.o.), and the Cmax is 272 ng/mL.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wister rats (6 weeks, 160-180 g) injected with Monocrotaline
Dosage: 2.5 mg/kg
Administration: Oral administration; daily; for 3 weeks
Result: Decreased symptoms of the pulmonary arterial hypertension (PAH) rats.
体内研究

PDE10A-IN-2 hydrochloride (compound 14 3HCL; 2.5 mg/kg; oral administration; daily; for 3 weeks) treatment decreases the typical symptoms of PAH in rats.
In Sprague-Dawley rats, the pharmacokinetic study of PDE10A-IN-2 hydrochloride (compound 14 3HCL; 10 mg/kg) shows the oral bioavailability up to ∼50%, and the T1/2 is 5.2 hours (p.o.), and the Cmax is 272 ng/mL.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wister rats (6 weeks, 160-180 g) injected with Monocrotaline
Dosage: 2.5 mg/kg
Administration: Oral administration; daily; for 3 weeks
Result: Decreased symptoms of the pulmonary arterial hypertension (PAH) rats.
性状Solid
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (159.48 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.5948 mL 7.9738 mL 15.9477 mL
5 mM 0.3190 mL 1.5948 mL 3.1895 mL
10 mM 0.1595 mL 0.7974 mL 1.5948 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服